First 12 patients with coronavirus disease 2019 (COVID-19) in the United States
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Abstract
Introduction More than 93,000 cases of coronavirus disease (COVID-19) have been reported worldwide. We describe the epidemiology, clinical course, and virologic characteristics of the first 12 U.S. patients with COVID-19.
Methods We collected demographic, exposure, and clinical information from 12 patients confirmed by CDC during January 20–February 5, 2020 to have COVID-19. Respiratory, stool, serum, and urine specimens were submitted for SARS-CoV-2 rRT-PCR testing, virus culture, and whole genome sequencing.
Results Among the 12 patients, median age was 53 years (range: 21–68); 8 were male, 10 had traveled to China, and two were contacts of patients in this series. Commonly reported signs and symptoms at illness onset were fever (n=7) and cough (n=8). Seven patients were hospitalized with radiographic evidence of pneumonia and demonstrated clinical or laboratory signs of worsening during the second week of illness. Three were treated with the investigational antiviral remdesivir. All patients had SARS-CoV-2 RNA detected in respiratory specimens, typically for 2–3 weeks after illness onset, with lowest rRT-PCR Ct values often detected in the first week. SARS-CoV-2 RNA was detected after reported symptom resolution in seven patients. SARS-CoV-2 was cultured from respiratory specimens, and SARS-CoV-2 RNA was detected in stool from 7/10 patients.
Conclusions In 12 patients with mild to moderately severe illness, SARS-CoV-2 RNA and viable virus were detected early, and prolonged RNA detection suggests the window for diagnosis is long. Hospitalized patients showed signs of worsening in the second week after illness onset.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon request.
Subject Area
- Addiction Medicine (343)
- Allergy and Immunology (666)
- Anesthesia (180)
- Cardiovascular Medicine (2630)
- Dermatology (222)
- Emergency Medicine (397)
- Epidemiology (12183)
- Forensic Medicine (10)
- Gastroenterology (756)
- Genetic and Genomic Medicine (4071)
- Geriatric Medicine (387)
- Health Economics (679)
- Health Informatics (2628)
- Health Policy (998)
- Hematology (362)
- HIV/AIDS (845)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (431)
- Neurology (3840)
- Nursing (209)
- Nutrition (571)
- Oncology (2011)
- Ophthalmology (582)
- Orthopedics (239)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (74)
- Pathology (471)
- Pediatrics (1109)
- Primary Care Research (449)
- Public and Global Health (6504)
- Radiology and Imaging (1390)
- Respiratory Medicine (869)
- Rheumatology (401)
- Sports Medicine (341)
- Surgery (441)
- Toxicology (52)
- Transplantation (185)
- Urology (165)